Preventing and controlling chlamydia--the silent STI--in people with HIV.
(Development and progression)
HIV (Viruses) (Control)
Chlamydia infections (Development and progression)
HIV infection (Development and progression)
HIV infection (Control)
Disease transmission (Development and progression)
Disease transmission (Control)
|Publication:||Name: Research Initiative/Treatment Action! Publisher: The Center for AIDS: Hope & Remembrance Project Audience: General; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 The Center for AIDS: Hope & Remembrance Project ISSN: 1520-8745|
|Issue:||Date: Summer, 2012 Source Volume: 17 Source Issue: 1|
|Product:||Product Code: 8000200 Medical Research; 9105220 Health Research Programs; 8000240 Epilepsy & Muscle Disease R&D NAICS Code: 54171 Research and Development in the Physical, Engineering, and Life Sciences; 92312 Administration of Public Health Programs|
|Organization:||Government Agency: United States. Centers for Disease Control and Prevention|
Abstract: Every year nearly 3 million people in the United States
get infected with Chlamydia trachomatis, the most frequently reported
bacterial sexually transmitted infection (STI) in this country. An
international review and a US study determined that about 5% of
HIV-positive people have chlamydia infection. Because chlamydia--the
silent STI--often causes no symptoms, regular screening of sexually
active people is essential. Risk factors for chlamydia infection include
prior chlamydia, multiple sex partners, unprotected sex, drug use during
sex, younger age, and a CD4 count below 200 cells/[mm.sup.3]. Rectal
chlamydia infection can boost the risk of HIV infection in MSM nearly 9
times, and chlamydia doubles the risk of HIV shedding in the genital
tract. Treating chlamydia significantly lowers cervical HIV shedding.
Various strategies for getting antibiotics to sex partners of people
diagnosed with chlamydia--without requiring partners to visit a clinic
for an exam--have proved effective in treating more partners and
preventing reinfection in index cases. But such strategies have some
drawbacks. Chlamydia treatment guidelines are the same for people with
and without HIV. Some research suggests that the simplest
regimen--single-dose azithromycin--may be less than optimal for people
with asymptomatic rectal chlamydia.
Chlamydia poses an insidious and ongoing threat to HIV-positive people--insidious because it usually causes no symptoms and so can easily go undetected, ongoing because people with HIV often remain sexually active and so risk picking up or passing along another STI.
Chlamydia trachomatis accounts for the highest proportion of reported bacterial STIs in the United States, about 3 million new infections yearly, (1) representing about 2.7% of adults between 18 and 44 years old. And people with HIV do their share in sustaining that high rate. A systematic review of HIV-positive people across the world (but mostly in North America and Europe) figured that 5% have chlamydia. (2) Chlamydia proved the fourth most prevalent STI in this review, following Trichomoniasis (at 18.8%) and syphilis and gonorrhea (tied for second at 9.5%).
Chlamydial urethritis usually does provoke symptoms in men) but most women with chlamydia-induced pelvic inflammatory disease have symptoms so mild or nonspecific that they never seek medical care. (4) (A handout for patients at the end of this article lists chlamydia symptoms and other chlamydia prevention and care pointers.) Yet 20% of women with pelvic inflammatory disease become infertile, 18% succumb to "debilitating, chronic pelvic pain," and 9% face life-threatening tubal pregnany. (4) C trachomatis infection during pregnancy can lead to postpartum endometritis in mothers and to conjunctivitis or pneumonia in infants. (4)
Gay and bisexual men with and without HIV run a risk of asymptomatic rectal chlamydia if they practice receptive anal intercourse. A 3076-man study in Britain charted a 38% prevalence of HIV and rectal chlamydia coinfection, and two thirds of rectal infections caused no symptoms. (5) Those findings prompted the investigators to call rectal chlamydia "a reservoir of undiagnosed infection" in men who have sex with men (MSM).
Besides causing pelvic inflammatory disease in women and epididymitis in men, chlamydia can trigger conjunctivitis or sexually acquired reactive arthritis in adults. (4) And as with most STIs, chlamydia heightens the risk of acquisition or transmission of HIV and other sexually transmitted pathogens.
Although the CDC and other agencies and professional groups offer lengthy and detailed advice on chlamydia screening, diagnosis, and treatment in people with and without HIV, chlamydia experts acknowledge big holes in understanding the natural history of this pervasive infection. In 2008 the CDC gathered an advisory group to sort out what's known--and not known--about the course of chlamydia in infected people. (6) They homed in on four "key questions" whose answers bear heavily on chlamydia prevention and care guidelines. After parsing available data, the panel agreed that no one knows the answers (Table 1).
With those limits in mind, this review analyzes chlamydia risk factors, prevalence, and incidence in people with HIV; the impact of chlamydia on HIV risk and progression; screening for and diagnosing chlamydia in people with HIV; preventing chlamydia; and treating chlamydia in people with HIV. The article is limited to C trachomatis serovars that cause urethritis, pelvic inflammatory disease, and the other conditions mentioned above. Three C trachomatis serovars can cause lymphogranuloma venereum, a lymphatic system infection that spawned a concerning spate of outbreaks among MSM over the past decade, (7,8) but this article will not cover lymphogranuloma venereum.
Almost 3 million in US (many with HIV) have chlamydia
In 2011 a 37-study systematic review of STIs acquired after people became infected with HIV figured chlamydia prevalence at 5%. (2) The analysis embraced 708,296 HIV-positive people, and 27 of the studies were from North America, Europe, or Australia. The highest STI coinfection prevalence came among people with newly diagnosed HIV, a result possibly reflecting a heightened HIV acquisition risk in people with an STI. Overall STI prevalence did not differ between men and women or between people taking or not taking combination antiretrovirals. The latter finding, these researchers cautioned, "suggests that STI co-infections could undermine efforts to use HIV treatments for prevention by increasing genital secretion infectiousness." (2)
A study of 235 HIV-positive gay men seen in Sydney in 2004 and 2005 found that 2% had urethral chlamydia and 6% had anal chlamydia, and these rates did not differ from prevalence in an HIV-negative cohort of gay men. (9) At four HIV/STI clinics in London, a study of 3076 MSM seen in 2005 and 2006 recorded rectal and urethral chlamydia rates of 8% and 5%. (5) Rectal rates reflected chlamydia variants causing lymphogranuloma venereum (LGV) as well as non-LGV variants. Of the 247 rectal infections, 171 (69%) evoked no symptoms and so would have been missed without screening.
Although chlamydia and most other STIs reach their highest prevalence in teens and young adults, an eye-opening 1996-2003 study of people attending genitourinary medicine clinics in the British Midlands shows that people over 44 years old contribute their share to STI prevalence. (10) These investigators counted 4445 STI episodes in people 45 and older during the study period, including 801 chlamydia diagnoses (18%). Compared with 1996, the chlamydia rate was 3.6 times higher in 2003 (95% confidence interval [CI] 2.55 to 5.06, P < 0.0001). That jump was bigger than the overall 2.27 times rise in STI prevalence. Over the study period, the overall STI rate rose more in men (rate ratio [RR] 2.51, 95% CI 2.14 to 2.94, P < 0.0001) than in women (RR 1.85, 95% CI 1.50 to 2.28, P < 0.0001). The researchers did not report HIV rates.
Chlamydia incidence remains poorly studied in HIV populations. The largest recent study involved 4461 HIV-positive people in the US Military Natural History cohort monitored 6 months or later aider their positive HIV test. (11) Through an average follow-up of 7.08 years, 278 people (6%) picked up chlamydia, a rate similar to the 5% chlamydia prevalence recorded in the 37-study systematic review of 708,296 people with HIV. (2) In the military study, chlamydia or gonorrhea rates were significantly higher in younger, male African Americans with a history of either STI.
A 2004-2006 study of 557 HIV-positive people in four US cities detected new chlamydia infections only in 365 MSM, not in 73 men who have sex with women or 119 women. (12) In MSM, incidence 6 months after they entered the cohort stood at 5% for anorectal chlamydia and at 2% for oropharyngeal chlamydia (Table 2).
A single-center nurse-led self-screening program for chlamydia and gonorrhea in Brighton, UK, involved 976 screens done over 8 months in HIV-positive people with no STI symptom. (13) Screening detected 143 infections that would have been missed without this program. In MSM incidence measured 9.8% for rectal chlamydia, 2.6% for urethral chlamydia, and 1.7% for pharyngeal chlamydia. Chlamydia incidence in heterosexual men and women was 2.1%.
In the general US population, yearly chlamydia case rates among women vaulted 54% from 2000 to 2010 (Figure 1). (14) The CDC cautions that this inexorable case-rate inflation could reflect more intense screening, more sensitive diagnostic tests, or improved surveillance and reporting systems, (4) but "persistently high infection rates" probably figure heavily in the equation.
A prospective study of 1427 HIV-negative MSM recruited from 2001 through 2004 in Sydney recorded urethral and anal chlamydia incidence rates of 7.43 and 4.98 per 100 person-years, higher than the 3.49 and 2.96 rates for urethral and anal gonorrhea. (15) Chlamydia incidence in these HIV-negative MSM far outstripped incidence in the general population of US women in 2010--610.6 per 100,000 in the US women (14) and 7430 and 4980 per 100,000 for urethral and anal chlamydia in the Australian MSM. In these men unprotected anal intercourse with HIV-positive partners and frequent insertive oral sex raised the risk of urethral gonorrhea or chlamydia, and receptive unprotected anal intercourse made anal infections more likely.
Researchers have not directly tried to gauge the impact of active chlamydia infection on HIV incidence, though evidence from a systematic review described above supports that intuitive association. (2) One should not assume, however, that wider chlamydia control measures will necessarily trim HIV incidence. A 2011 Cochrane Database review of four trials "failed to confirm the hypothesis that STI control [through biomedical intervention] is an effective HIV prevention strategy" in the general population. (16) However, all these trials took place in rural Africa. The Cochrane team did find "other compelling reasons why STI treatment services should be strengthened."
Chlamydia risk factors in people with and without HIV
Several big studies identified independent predictors of chlamydia and other STIs in HIV-positive people and the general population (Tables 3 and 4). (12,17-21) Being young raises the risk of chlamydia. Having lots of sex--and lots of risky sex--raises the risk. But these are obvious indicators; a few risk factors are less evident.
For starters, "young" doesn't necessarily mean under 25, at least not among gay and bisexual men. A study of 659 HIV-positive MSM in the Netherlands found that being 40 to 44 rather than older more than doubled the odds of chlamydia, gonorrhea, or syphilis (17) (Table 3). In Australia a study of 3805 MSM seeking care at STI clinics found that those 30 to 39 had a 42% higher risk of chlamydia than older men (20) (Table 4). In this study the heightened risk was similar in MSM under 25 and MSM 25 to 29.
Analysis of HIV-positive US SUN Study participants found that MSM who had 4 or more sex partners in the 6 months before STI testing ran a higher risk of both prevalent and incident chlamydia, gonorrhea, or syphilis (12) (Table 3). Multiple substance abuse inflated the odds of incident STIs 5 times in these MSM. Among HIV-positive MSM in the Netherlands, sharing sex toys or having an enema before sex (a signal of receptive anal intercourse) more than doubled the odds of chlamydia, gonorrhea, or syphilis (17) (Table 3). In these MSM using drugs during sex also more than doubled the STI risk. Among Australian MSM seen in STI clinics, smoking cigarettes boosted the odds of chlamydia 19% (20) (Table 4). In the same study inconsistent condom use in the past 3 months made chlamydia 50% more likely in both MSM and women.
A study of HIV-positive pregnant women in Western Europe and Ukraine (Table 3) determined that a CD4 count below 200 cells[mm.sup.3], being single, and having an injection drug user (IDU) sex partner made chlamydia, syphilis, or Trichomonas vaginalis more likely. (18)
A 48-state US study of the general population found significant links between poverty or income inequality and chlamydia (Table 4). (19) These associations are reflected in two other general-population studies that traced ties between chlamydia risk and minority status in US MSM (22) or Australian men and women (20) (Table 4).
Sociodemographic variables must also figure in consistent correlations between childhood sexual abuse and risk of HIV and other STIs. A 2004-2005 analysis of the US National Epidemiologic Survey on Alcohol and Related Conditions found that women or men reporting abuse during childhood ran a higher risk of HIV or other STIs as adults. (22) Compared with people not abused as children, the STI risk was higher in abused men or women who also reported same-sex partners or attractions than in those who did not.
A study of 485 girls and 51 boys who were 13 or younger and evaluated for sexual abuse at four US centers found that 3% of girls had chlamydia and 3% had gonorrhea. (23) No children tested positive for HIV and no boys had any STI, but 40 of 485 girls (8%) had one or more STIs. Girls with vaginal discharge had higher STI rates than girls without discharge (24.5% versus 6%), but 10 girls with STIs had normal physical exams. And 27 of 40 girls with an STI (67.5%) had normal or nonspecific anogenital exams. One expert in this field counsels that "specific [sexually transmitted] infections in prepubertal children, such as Neisseria gonorrhoeae or Chlamydia trachomatis, are due to abusive contact and should be reported to Child Protective Services." (24) Recently abused children, she adds, should be considered for HIV postexposure prophylaxis.
Adults who have had one STI are prime candidates for a second STI within a year, according to results of a 2419-person analysis of RESPECT-2, a study of HIV prevention counseling in STI clinics in Denver, Long Beach, and Newark. (21) Follow-up continued for a year after 1236 women and 1183 men visited the clinic. During 8129 3-month follow-up intervals, 25.8% of women had one or more new STIs, including 9.4% with chlamydia. Among the 1183 men, 14.7% had a new STI, including 9.4% with chlamydia. Two thirds of people with a new STI reported no symptoms. Table 4 summarizes risk factors for a new STI in this study.
In England an 18-month 2002-2003 study of 1971 young women recruited from general practice, family planning clinics, and genitourinary medicine (GUM) clinics found a high chlamydia reinfection rate in all three settings. (25) Chlamydia incidence in these 16- to 24-year-old women was higher in GUM clinics than in family planning clinics or general practices (10.6 versus 6.4 versus 4.9 per 100 person-years). But reinfection rates were high in all three settings (21.1 versus 22.3 versus 29.9 per 100 person-years respectively). Finding a new sex partner and failure to treat all partners made reinfection more likely.
An Australian study supports the intuitive assumption that MSM seeking HIV postexposure prophylaxis will likely benefit from STI screening. (26) This 2001-2004 study found that 253 of 298 MSM (85%) agreed to STI testing. While 4.5% had rectal chlamydia, 2.5% had rectal gonorrhea. Only 6 men with an STI (19%) had symptoms at screening.
How chlamydia sets up infection and spreads
C trachomatis infects epithelial cells at mucosal surfaces (Figure 2), igniting an inflammatory response that can lead to tissue damage and scarring upon reinfection. (27) But little was known about how chlamydia sets off and sustains an inflammatory response until US researchers infected cervical and colonic epithelial cells with C trachomatis and C psittaci. (28) Infection prompted secretion of the proinflammatory cytokines IL-6, IL-8, GRO alpha, and GM-CSF. While other invasive bacteria provoke rapid but transient cytokine responses, chlamydia induced a response that began 20 to 24 hours after infection and persisted throughout the chlamydia growth cycle, which lasts 2 to 4 days.
This work also showed that IL-1alpha, which is released during lysis of chlamydia-infected epithelial cells, may amplify the inflammatory response by churning up additional cytokines in uninfected neighboring cells. These investigators believe their findings "suggest a novel concept for chlamydial pathogenesis wherein the acute host response to chlamydia in the genital tract, and at other mucosal surfaces, is primarily initiated and sustained by epithelial cells, the first and main targets of chlamydial infection." (28)
[FIGURE 2 OMITTED]
Like HIV, C trachomatis can jump from one person to another during vaginal or rectal sex. (1) But while oral transmission of HIV is inefficient, C trachomatis can exploit the oral route with relative ease, (1) a factor that contributes to high chlamydia rates in sexually active people. C trachomatis may also pass from mother to infant during vaginal delivery.
Chlamydia raises risk of HIV infection and progression
Rectal chlamydia infection can boost the risk of HIV infection in MSM nearly 9 times, (29) and chlamydia doubles the risk of HIV shedding in the genital tract, (30) upping the odds of HIV transmission from people infected with C trachomatis. Treating chlamydia significantly lowers cervical HIV shedding. (31)
A retrospective cohort study reported in 2010 by the San Francisco Department of Public Health assessed how the number of rectal infections with C trachomatis or N gonorrhoeae in the past 2 years affects the risk of getting infected with HIV. (29) Among 541 initially HIV-negative men studied, 27 (5%) got infected for an estimated annual HIV incidence of 2.25%. Two rectal chlamydia infections or two rectal gonorrhea infections in the past year inflated the risk of HIV seroconversion nearly 9 times (hazard ratio [HR] 8.85, 95% CI 2.57 to 30.4). An early syphilis diagnosis in the past 2 years quadruped the risk (HR 4.04, 95% CI 1.19 to 13.79).
A history of any STI in an HIV-negative woman with an HIV-positive male partner more than doubled the odds that the woman would get infected with HIV. (32) This 10-year northern California study involved 360 HIV-positive men and their negative female partners and 82 HIV-positive women and their negative male partners. More than 90% of couples were monogamous. Because this study was reported in mid-1997, follow-up largely occurred before the triple-therapy era. Sixty-eight of 360 initially negative women picked up HIV, compared with only 2 of 82 initially negative men (18.9% versus 2.4%). A history of any STI in a female partner more than doubled the odds of male-to-female HIV transmission (OR 2.6, 95% CI 1.4 to 5.1).
Meta-analysis of 39 studies that weighed the impact of genital tract infections on genital HIV shedding determined that chlamydia nearly doubled the odds, while urethritis or cervicitis from any cause tripled the odds (at the following odds ratios and 95% CIs). (30)
* Chlamydia infection: OR 1.8, 95% CI 1.1 to 3.1
* Gonorrhea: OR 1.8, 95% CI 1.2 to 2.7
* Vulvovaginal candidiasis: OR 1.8, 95% CI 1.3 to 2.4
* Urethritis: OR 3.1, 95% CI 1.1 to 8.6
* Cervicitis: OR 2.7, 95% CI 1.4 to 5.2
These researchers stressed that "these infections are likely to be particularly important in promoting sexual transmission and mother-to-child intrapartum transmission of HIV-1." (30) Another pooled analysis of three studies in women also found that chlamydia nearly doubled the odds of HIV shedding (OR 1.85, 95% CI 1.1 to 3.2, P = 0.02). (33)
Given findings like these, it is not surprising that treating cervicitis decreases HIV shedding. (31) This study involved 36 HIV-positive women treated for cervicitis in Mombasa, Kenya; 16 had N gonorrhoeae, 7 had C trachomatis, and 13 had nonspecific cervicitis. After treatment of cervicitis, cell-free and cell-associated HIV-1 RNA fell from 4.05 to 3.24 log10 copies/ swab overall (P = 0.001) and from 4.21 to 3.19 log10 copies/swab in women with chlamydia (P = 0.02). Prevalence of HIV-1 DNA in cells dropped from 67% before treatment to 42% after treatment (OR 2.8, 95% CI 1.3 to 6.0, P = 0.009).
A study of urine-based chlamydia and gonorrhea screening in a New Orleans HIV clinic used a mathematical model to estimate that treating 56 chlamydia infections and 46 gonorrhea infections may have averted 9 HIV infections in sex partners "and saved far more in future medical costs than the cost of the screening." (34)
Despite results of these two studies, (31,34) a 2011 Cochrane Database review of four trials could not confirm that treating STIs "is an effective HIV prevention strategy" in the general population. (16)
Screening and testing for chlamydia: urine is not enough
CDC chlamydia screening guidelines released in 2002 offer advice on when to screen women but not men in the general population. (4) The CDC recommends screening all women up to age 25 and older women with a higher chlamydia risk indicated by multiple sex partners, a history of STIs, or not using condoms consistently or correctly.
Health Resources and Services Administration (HRSA) HIV guidelines from 2011 outline chlamydia and gonorrhea screening guidance for women and men (Table 5). (3) For pharyngeal or rectal infection, HRSA recommends a nucleic acid amplification test (NAAT) or culture of an oral swab or a rectal swab. For urethral or cervical infections, HRSA recommends NAAT on a first-catch urine or urethral specimen (in men) or cervical specimen (in women). One STI expert notes that NAATs have a low positive predictive value in populations with low chlamydia prevalence, such as older adults, so "positive test results should be interpreted with caution, and consideration should be given to use of a second testing modality for confirmation of the results." (35)
Despite guidelines recommending frequent gonorrhea and chlamydia screening in people with HIV, a study of HIV-positive men in the Johns Hopkins University HIV cohort found that fewer than half were getting tested for these STIs. (36) Among 1110 men studied in this 1999-2008 analysis, chlamydia and gonorrhea testing rates upon clinic enrollment rose from 4% before 2003 to only 16.5% afterwards. The proportion of men ever tested for these STIs climbed from 34.2% before 2003 to 49.1% afterwards. Yet among 342 men ever tested, 5.2% had a positive result on their first test. A 2004-2010 analysis of HIV-positive men and women in 7 US cities found that syphilis testing rates reached 70% in 2009-2010, while chlamydia and gonorrhea testing rates languished below 40% in those years. (37)
Almost three quarters of 808 adults visiting a Colorado HIV counseling and testing center (71%) agreed to urine screening for C trachomatis, though only 8 of 560 urine samples processed (1.4%) were positive. (38) One third of those who declined urine screening did so because they had no STI symptoms, even though chlamydia infection is often asymptomatic.
Although urine screening is easy, it will probably miss a fair proportion of chlamydia infections, both in men and women. A San Francisco study of 5539 MSM seen at an STI clinic and 895 seen at a gay community health center found the highest chlamydia prevalence in rectal samples (7.9%), followed by urethral (5.2%) and pharyngeal (1.4%) sites. (39) More than half of chlamydia infections (53%) were nonurethral, and 85% of rectal infections were asymptomatic.
A study of people attending an STI clinic or one of three HIV clinics focused on those who reported anal intercourse or women with a high risk of chlamydia or gonorrhea. (40) More than 80% of chlamydia infections would have been missed if rectal samples had not been tested. Culture of rectal swabs had chlamydia sensitivities ranging from 36.1% to 45.7%, while sensitivities of two NAATs were 91.4% to 95.8% for PCR and 100% for transcription-mediated amplification (TMA). Specificities of the two NAATs were also high.
People reluctant to get tested for chlamydia at an STI clinic or their provider's office may try an Internet site offering STI testing. But a 2010 survey of such sites found them highly unreliable. (41) These researchers identified 27 US or international sites offering STI self-collection kits and services for chlamydia, gonorrhea, syphilis, and other STIs. Only two sites completed a mailed or e-mailed survey about these services. Six sites appeared to be invalid because mail or e-mail to them was returned undelivered. Only 5 of 7 sites that provided test kits returned results. Two sites that were sent urine samples never responded. Two kits yielded false-negative results, while two kits yielded correct positive results.
Chlamydia prevention that works: condoms and beyond
Behavioral interventions have proved successful in curbing the risk of chlamydia infection, as has a partner-delivered azithromycin program. But steady condom use is the surest way to prevent spreading or acquiring chlamydia. Both the CDC (1) and the Health Resources and Services Administrations (HRSA) (3) stress the reliability of condoms: "Male latex condoms, when used consistently and correctly," HRSA HIV guidelines say, "are highly effective in preventing sexual transmission of HIV and many other STIs, including syphilis, chlamydia, gonorrhea, and Trichomoniasis." (3)
Inconsistent condom use upped the odds of chlamydia infection by 50% in an Australian study of 3805 MSM (]table 4). (20) In the same study, women whose partners did not wear condoms consistently also had 50% higher odds of picking of chlamydia. CDC investigators examined the impact of consistent condom use in people enrolling in a trial of sex-counseling interventions at five publicly funded US STI clinics from 1993 through 1997. (42) Among 429 participants with known exposure to chlamydia or gonorrhea, consistent condom use sliced the odds of prevalent infection with one of those STIs by almost 60% (adjusted OR 0.42, 95% CI 0.18 to 0.99). Among 4314 participants with unknown exposure to chlamydia or gonorrhea, consistent condom use trimmed those odds by almost 20% (adjusted OR 0.82, 95% CI 0.66 to 1.01).
Some of the same CDC investigators conducted a systematic review of chlamydia and gonorrhea risk in 45 studies of condom use. (43) All studies assessed male condom use and were published from 1966 through 2004. Most studies had methodologic limitations, such as failing to distinguish between consistent and inconsistent condom use. Despite these limitations, which probably resulted in underestimates of condom effectiveness, in the overall analysis condoms did lower chlamydia and gonorrhea rates in both men and women.
Asking women with chlamydia to hand-deliver antibiotics to their sex partners may lower the reinfection risk in those women. A randomized trial conducted by the CDC involved 1787 women from 14 to 34 years old with uncomplicated genital C trachomatis infection diagnosed in 5 US cities. (44) The investigators randomized women to deliver a dose of azithromycin (a "partner pack") to each of their sex partners or to refer their sex partners for treatment.
Four months later, urine ligase chain reaction or polymerase chain reaction indicated a lower risk of chlamydia reinfection in women who took azithromycin to their partners (87 of 728, 12%) than in women who referred partners for treatment (106 of 726, 15%). Although that difference fell short of statistical significance (OR 0.80, 95% CI 0.62 to 1.05, P = 0.102), the CDC team suggested that patient-delivered treatment "may be an appropriate option for some patients" with uncomplicated chlamydia.
A randomized trial of expedited partner notification and treatment versus standard notification, described in the next section, found lower rates of persistent or recurrent chlamydia or gonorrhea in index patients. Two accelerated partner notification and treatment models tested in the UK, also described in the next section, documented higher chlamydia and gonorrhea treatment rates among partners benefiting from these approaches than among partners who received standard notification.
Three behavioral intervention studies found that these strategies cut the risk of chlamydia infection in adults and adolescents. "Intervention" is a term laden with visions of multimonth counseling conducted by specially trained (and richly paid) staff, but the Safe in the City approach involves only a video with STI prevention messages seen in the waiting room before appointments. (45) This study involved 38,635 people who came to publicly funded STI clinics in three US cities between December 2003 and August 2005. Participants were randomized to the usual waiting-room environment or to watch a 23-minute video showing couples overcoming barriers to safer-sex behaviors. After an average 14.8 months of follow-up, the risk of incident lab-confirmed chlamydia, gonorrhea, Trichomoniasis, syphilis, or HIV was about 10% lower in the intervention group, a significant difference (HR 0.91, 95% CI 0.84 to 0.99). To access and preview this video, go to http://www.safeinthecity.org.
The WILLOW Program involves four 4-hour sessions for women delivered over 4 consecutive weeks and emphasizing gender pride, maintaining current and identifying new network members, enhancing HIV transmission knowledge, improving communication and condom use skills, and developing healthy relationships (for details go to http://www. cdc.gov/hiv/topics/research/prs/resources/factsheets/ WILLOW.htm#ref1). A trial reported in 2004 randomized 366 HIV-positive women in Alabama and
Georgia to the WILLOW Program or to no intervention. (46) Through 12 months of follow-up, incidence of chlamydia or gonorrhea was about 80% lower in the WILLOW group (OR 0.19, P = 0.006). Women who completed WILLOW also reported significantly fewer episodes of unprotected vaginal intercourse and were significantly less likely to report never using condoms. The CDC ranks WILLOW as one of its "best-evidence" interventions to prevent infection with HIV and other STIs.
A culturally tailored STI/HIV intervention for African-American girls and young women involves two 4-hour group sessions and 4 telephone contacts during a 1-year period. (47) A trial randomized 715 youngsters seeking sexual health services to receive the intervention or standard care. Participants completed a computer-assisted self-interview and gave self-collected vaginal specimens for STI testing. Girls and women randomized to the interview had a 35% lower risk of a new chlamydia infection (risk ratio [RR] 0.65, 95% CI 0.42 to 0.98, P = 0.04) and a 75% lower risk of recurrent chlamydia (RR 0.25, 95% CI 0.08 to 0.83, P = 0.02). Participants in the intervention group also reported a higher proportion of condom-protected sex acts in the previous 60 days and a higher rate of condom use at last intercourse.
STI screening itself may temper risk-taking behavior, according to results of a study in 636 sexually active African-American teens in two US cities with high STI prevalence. (48) Among adolescents screened for chlamydia, gonorrhea, and Trichomoniasis, the 6.6% with positive tests received treatment and counseling, while those with negative results received no further intervention. Among the 85% of study participants who completed 3- and 6-month follow-up visits, teens with a positive STI result lowered their number of vaginal and oral sex partners and the number of unprotected sex acts. STI-negative adolescents made no changes in numbers of partners or unprotected sex acts. STI testing at the 6-month point determined that 4.3% of initially STI-negative youngsters had a positive test.
Work is under way to develop a T-cell vaccine against chlamydia infection. (49) Researchers at the British Columbia Centre for Disease Control and the University of British Columbia formulated a vaccine with three chlamydia T-cell antigens that generated protection against infection in mice. These investigators cautioned that "an ongoing challenge for chlamydia vaccine research remains the discovery of strategies that maximize the protective effects of immune T cells while simultaneously preventing such cells from causing immune-mediated tissue damage."
Benefits reaped with better partner notification
Recent research details the benefits of prompt notification and treatment of chlamydia patients' partners, and the CDC provides extensive advice on partner notification for chlamydia, HIV, and other STIs. (50) Yet chlamydia partner notification rates in the United States were abysmal when last evaluated. (51) In 1998 researchers asked US health departments in areas with the highest reported rates of chlamydia, syphilis, gonorrhea, and HIV to indicate how many people with these infections were interviewed for partner notification. Only 26,487 of 228,210 chlamydia patients (12%) were asked to provide partner contact information, below the rates for gonorrhea (17%), HIV (52%), or syphilis (77%). Twenty-seven of 60 responding health departments (45%) provided no routine partner notification services to chlamydia patients.
Given this lackluster health-department performance, clinicians might be expected to take up the slack. But that wasn't happening the last time the CDC checked. A random survey of 7300 providers reported in 2002 found that 80% of respondents told chlamydia patients to notify their partners rather than doing so themselves. (52) And only 20% of providers followed up with patients to see if partners had been referred for treatment.
The CDC says all sex partners of people with chlamydia should be contacted and tested, (1) and the Health Resources and Services Administration (HRSA) says partners should be treated empirically if they had sex with the index patient within 60 days since that person's symptoms began. (3) If a person diagnosed with chlamydia cannot remember sex partners within the past 60 days, the most recent sex partners before that should be contacted and treated. The CDC urges people diagnosed with chlamydia to avoid sex with partners who are not examined and treated. (1)
HRSA underscores the potential value of antibiotic "partner packs" delivered by the index patient to partners who may be unlikely to come to the clinic for evaluation. (3) This approach, described in the preceding section, may result in a lower reinfection rate among index patients. (44) A British trial of a similar but more comprehensive partner-treatment approach is described below. HRSA notes that most recurrent chlamydia infections occur in people whose sex partners are not treated. (3) Anyone treated for chlamydia should be retested about 3 months later, regardless of whether they believe their sex partners got treated. (1)
In 2008 the CDC released comprehensive guidelines on partner notification and treatment for people diagnosed with HIV, chlamydia, and other STIs, including a flowchart detailing the steps in contacting, notifying, treating, and monitoring partners (Figure 3). (50) Among other things, these guidelines cover (1) counseling index patients about reducing their risk for acquiring or transmitting infection to others and referring them for additional prevention services, if needed, (2) notifying partners of their exposure, (3) counseling partners about reducing their risk for acquiring HIV infection and other STIs and referring them for additional prevention services, if needed, (4) offering partners STI/HIV testing, and (5) treating partners or linking them to medical care and treatment. The CDC also suggests which patients diagnosed with chlamydia fall into a high-priority group for partner notification, and which partners should be considered high-priority: (50)
High-priority index patients for partner services, regardless of the STI:
* Pregnant women and male index patients with pregnant partners
* Index patients suspected of or known to be engaging in behaviors that substantially increase risk of transmission to multiple partners (for example, those with multiple sex partners or druginjection partners)
* Persons coinfected with HIV and one or more other STIs
* Persons with recurrent STIs
High-priority index patients for partner services for chlamydia, syphilis, and gonorrhea:
* Persons with clinical signs or symptoms suggesting infection
* Infected persons from high STI prevalence areas
Partners with the highest priority for notification, regardless of the STI:
* Female partners who are known or likely to he pregnant
* Partners suspected of or known to be engaging in behaviors that substantially increase the risk for transmission to multiple other persons
* Partners with whom the index patient reports having had unprotected anal or vaginal sex
[FIGURE 3 OMITTED]
To determine whether faster notification and treatment of chlamydia and gonorrhea patients' partners would lower rates of persistent or recurrent infection in the index case, researchers planned a randomized trial of expedited treatment (patients offered medication to give to sex partners or offered contact of partners by staff who gave partners medication without a clinic exam) or standard referral (patients asked to refer partners for treatment and offered assistance in finding partners). (53) Patients included women and heterosexual men, but not MSM.
Three to 9 weeks after index patients got treated for chlamydia or gonorrhea, persistent or recurrent infection could be detected in 92 of 929 people (10%) assigned to expedited partner treatment and in 121 of 931 (13%) assigned to standard partner referral. (53) Relative risk of persistent or recurrent gonorrhea or chlamydia infection was about 25% lower in the expedited group (RR 0.76, 95% CI 0.59 to 0.98). When the researchers assessed the impact of expedited partner treatment on the two STIs separately, the persistent or recurrent infection rate was significantly lower for gonorrhea (3% versus 11%, P = 0.01), but that difference fell short of statistical significance for chlamydia (11% versus 13%, P = 0.17). These researchers noted three potential disadvantages to treating partners without evaluating them:
* "Some partners may have allergic reactions or other drug-related adverse effects.
* "Partners treated without a clinical evaluation may have concurrent STIs identifiable only if they seek medical care.
* "An opportunity may be lost to counsel sex partners to refer their other partners for evaluation and treatment." (53)
On the basis of these findings, the investigators argued that "the inadequacies of current approaches to partner notification and the persistence of unacceptably high levels of morbidity from sexually transmitted infections in the United States should motivate both clinicians and public health authorities to incorporate patient-delivered partner therapy and other approaches to expedited care of partners into clinical and public health policies." (53)
British researchers conducted a preliminary, nonrandomized comparison of two accelerated partner therapy (APT) models and routine partner notification for partners of people with a lab diagnosis of C trachomatis and/or N gonorrhoeae or nongonococcal urethritis (men only). (54) The study involved 226 adults enrolled in a sexual health clinic or a genitourinary medicine clinic. The researchers did not specify how many were women, heterosexual men, or MSM.
The two accelerated partner therapy models involved (1) a hotline that sex partners called for a phone consultation with a qualified provider or (2) a pharmacy that sex partners visited for consultation. In both models partners picked up or received from the index patient an "APT pack" including (1) 1 g of azithromycin or 400 mg of cefixime, (2) relevant drug information sheets, (3) a urine NAAT sample collection kit for C trachomatis and N gonorrhoeae and appropriate packaging for mailing samples back to the study lab, (4) condoms, and (5) full details of the study. Partners in the comparison group had to attend the clinic for evaluation and treatment. Both APT options also featured an "assertive invitation" to the partner to get fast-track HIV and syphilis tests at a local sexual health clinic.
While 42 of 117 of contactable partners (36%) reached by routine partner notification got treated, 80 of 135 partners (59%) reached by the hotline and 29 of 44 (66%) who visited a pharmacy were treated (P = 0.003 and P = 0.001 compared with routine partner notification). From 40% to 60% of partners in the accelerated partner therapy groups returned urine samples for STI testing, but almost none followed up for HIV or syphilis testing. The investigators hope to test these approaches in a cluster-randomized trial.
A stochastic simulation model estimated the impact of chlamydia screening coverage and partner notification on positivity in the United States. (55) The model described pair formation and dissolution in an age-structured heterosexual population of highly sexually active people. These researchers figured the impact of a chlamydia screening program reaching 20%, 35%, 50%, and 65% of women 15 to 24 years old, male partner notification rates of 20%, 40%, and 55%, screening rates of 20% and 35% in 15- to 24-year-old men, and female partner notification rates of 25% and 40%. The model estimated a 23% reduction in chlamydia positivity by increasing screening 3-fold or partner notification 2-fold.
Treating chlamydia in people with HIV
Treatment of C trachomatis infection is the same in people with HIV as in those without HIV. (3,56) Two regimens top the recommendation list:
* A single 1-g oral dose of azithromycin
* A 100-mg oral dose of doxycycline twice daily for 7 days
One-time azithromycin is preferred because of its simplicity. The CDC and the Health Resources and Services Administration (HRSA) guidelines for people with HIV list four alternative regimens: (3,56)
* Erythromycin base 500 mg orally four times a day for 7 days
* Erythromycin ethylsuccinate 800 mg by mouth four times a day for 7 days
* Ofloxacin 300 mg by mouth twice daily for 7 days
* Levofloxacin 500 mg by mouth once daily for 7 days
For pregnant women, the CDC and HRSA recommend a single 1-g oral dose of azithromycin or 500 mg of amoxicillin by mouth three times a day for 7 days. (3'56) CDC guidelines also spell out advice on treating chlamydia in infants and children. (56)
HRSA guidelines suggest providers advise patients to take medications with food if they feel nauseated and to call immediately if they experience vomiting or cannot take their medications. (3) Treated individuals should abstain from sex for 7 days after single-dose azithromycin or until a 7-day course is completed.
Except for pregnant women, infants, and children, the CDC does not recommend repeat testing 3 to 4 weeks after therapy "unless therapeutic compliance is in question, symptoms persist, or reinfection is suspected." (56) (Results of work described below suggest a test for cure may be advisable in people with asymptomatic rectal chlamydia. (57)) If chlamydia symptoms persist after treatment, HRSA recommends evaluating patients for possible reinfection, treatment failure, or a different cause of symptoms. (3) If the provider suspects treatment failure, HRSA recommends culture and antimicrobial sensitivity testing.
The CDC recommends rescreening all men and women treated for C trachomalis 3 months after they finish therapy, "regardless of whether they believe that their sex partners were treated." (56) If a person cannot be retested 3 months after treatment, the CDC advises retesting whenever that person has a follow-up visit in the 12 months after finishing therapy.
Does single-dose azithromycin work consistently for people with asymptomatic rectal gonorrhea, a common presentation in MSM? A case series at an Edinburgh genitourinary medicine clinic suggests no. (57) Edinburgh investigators reviewed all 101 cases of rectal chlamydia diagnosed from June 2005 to June 2006. After excluding symptomatic cases, they counted 9 failures of single-dose azithromycin in 68 people for a failure rate of 13%. The researchers believe this result "suggests that single-dose azithromycin may be a less than effective treatment in asymptomatic rectal C trachomatis infection" and that "the potential treatment failure rate with this regimen emphasizes the need for a test of cure at the appropriate interval following treatment to ensure clearance of infection." (57)
In a 37-study systematic review of STIs acquired by people already infected with HIV, taking combination antiretroviral therapy did not affect STI incidence. (2) On the basis of this finding, the investigators cautioned that "STI co-infections could undermine efforts to use HIV treatments for prevention by increasing genital secretion infectiousness." (2)
Chlamydia care reminders for HIV providers
* Chlamydia is the most prevalent bacterial STI in the United States and may affect 1 in 20 people with HIV.
* Because chlamydia infection may remain asymptomatic, routine screening of sexually active people is often the only way to detect it.
* All sexually active HIV-positive people should be screened for chlamydia at their first HIV visit. Men should be retested every 3 to 6 months and women every 6 to 12 months, depending on their risk of acquiring STIs.
* Screen all sites of possible chlamydia exposure, including urethral, cervical/vaginal, and rectal samples. Urine-based screening alone is inadequate.
* Besides younger age, multiple sex partners, and unprotected sex, other factors associated with chlamydia in people with HIV include a prior STI, substance abuse, drug use during sex, smoking, and sharing sex toys.
* Chlamydia can be transmitted during oral, vaginal, or rectal sex or during vaginal delivery.
* STI prevention interventions do not have to be costly or complicated. Watching a 23-minute video in an STI clinic waiting room lowered incidence of chlamydia, HIV, and other STIs in a randomized trial. (To access and preview this video, go to http://www.safeinthecity.org.)
* Because many health departments do not have routine partner notification programs for patients with chlamydia, many providers will have to perform this essential service themselves.
* Partners of chlamydia patients should be treated empirically if they have had sex with the diagnosed patient in the past 60 days.
Pointers on chlamydia prevention and care for people with HIV
1 * Chlamydia infection often has no physical signs or symptoms, so you may not know you're infected unless you get tested regularly.
2 * Sexually active men with HIV should be tested for chlamydia every 3 to 6 months, and sexually active women should be tested every 6 to 12 months.
3 * How often a person gets tested depends on their individual risk of chlamydia infection.
4 * People with a high risk of chlamydia infection include (1) those who have already had chlamydia, (2) those with many sex partners, (3) those who use drugs or alcohol during sex, (4) those who have sex without a condom, (5) younger people, and (6) people with a CD4 count under 200.
5 * Chlamydia can pass from one person to another during oral, vaginal, or rectal sex, and it can pass from a mother to an infant during vaginal delivery.
6 * Using male latex condoms correctly is the surest way to protect yourself from chlamydia.
7 * If you get chlamydia, letting your sex partners know is very important both so they can be treated and so you can avoid getting infected by them again.
8 * If you get treated for chlamydia, do not have sex for 7 days after you start treatment. After the treatment period, do not have sex with partners who have not been tested for chlamydia--and treated if necessary.
9 * Taking chlamydia drugs with food can lower the risk of nausea. If chlamydia drugs make you throw up, contact your provider immediately.
Sources: US Department of Health and Human Services Health Resources and Services Administration. Guide for HIV/AIDS Clinical Care. January 2011. http://hab.hrsa.gov/deliverhivaidscare/dinicalguide11/; Centers for Disease Control and Prevention. Chlamydia--CDC fact sheet, http://www.cdc.gov/std/chlamydia/stdfact-chlamydia.htm.
Possible signals of chlamydia infection
Chlamydia infection may cause no pain, discomfort, or any other signals of infection. But sometimes people infected with chlamydia feel pain or see signs in sex organs, in the anus or rectum (in people who practice anal sex), or in the abdomen or pelvis. If you notice one or more of the following signs, stop having sex. If these problems persist, see your healthcare provider as soon as possible.
* Urination, penis, testicles
Increased urinary frequency or urgency
Fluid with odor leaking from urethra (urine canal)
Red or swollen urethra
Incontinence (inability to control urination)
Pain on urination
Tenderness, swelling, or pain in testicles
* Anus, rectum
Rectal pain or bleeding
Fluid leaking from the rectum
Pain or burning on urination
* Sex organs
Fluid with odor leaking from the vagina
Pain during sexual intercourse
Bleeding between menstrual cycles
* Abdomen, pelvis
Abdominal or pelvic pain
Low back pain
* Mouth, throat
* Anus, rectum
Rectal pain or bleeding
Fluid leaking from the rectum
Sources: US Department of Health and Human Services Health Resources and Services Administration. Guide for HIV/AIDS Clinical Care. January 2011. http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/; Centers for Disease Control and Prevention. Chlamydial--CDC fact sheet, http://www.cdc.gov/std/chlamydia/stdfact-chlamydia.htm.
(1.) Centers for Disease Control and Prevention. Chlamydia--CDC fact sheet, http://www.cdc.gov/std/chlamydia/ stdfact-chlamydia.htm.
(2.) Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011;87:183-190.
(3.) US Department of Health mid Human Services Health Resources and Services Administration. Guide for HIV/AIDS clinical care. January 2011. http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/.
(4.) Centers for Disease Control and Prevention. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. MMWR Recomm Rep. 2002;51:No. RR-15. http://www.cdc.gov/std/LabGuidelines/rr5115.pdf.
(5.) Annan NT, Sullivan AK, Nori A, et al. Rectal chlamydia--a reservoir of undiagnosed infection in men who have sex with men. Sex Transm Infect. 2009;85:176-179.
(6.) Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis. 2010;201(suppl 2):S104-S113. http://jid.oxfordjournals.org/content/201/ Suppleraent_2/S104.long.
(7.) Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis. 2010;29:917-925.
(8.) Nieuwenhuis, RF, Ossewaarde JM, Gotz HM, et al. Resurgence of lymphogranuloma venereum in western Europe: an outbreak of Chlamydia trachonuttis serovar L2 procitis in the Netherlands among men who have sex with men. Clin Infect Dis. 2004;39:996-1003.
(9.) Jin F, Prestage GP, Zablotska I, et al. High rates of sexually transmitted infections in HIV positive homosexual men: data from two community based cohorts. Sex Transm Infect. 2007;83:397-399. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2659038/?tool=pubmed.
(10.) Bodley-Tickell AT, Olowokure B, Bhaduri S, et al. Trends in sexually transmitted infections (other than HIV) in older people: analysis of data from an enhanced surveillance system. Sex Transm Infect. 2008;84:312-317. http://sti.bmj.com/content/ 84/4/312.1ong.
(11.) Spaulding AB, Lifson AR, Iverson ER, et al; the Infectious Disease Clinical Research Program HIV Working Group. Gonorrhoea or chlamydia in a US military HIV-positive cohort. Sex Transm Infect. 2012 Jan 17. Epub ahead of print.
(12.) Mayer KH, Bush T, Henry K, et al. Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. Sex Transm Dis. 2012;39:1-7.
(13.) Soni S, White JA. Self-screening for Neisseria gonorrhoeae and Chlamydia trachomatis in the human immunodeficiency virus clinic high yields and high acceptability. Sex Transm Dis. 2011;38:1107-1109.
(14.) Centers for Disease Control and Prevention. Chlamydia profiles, 2010. April 3, 2012. http://www.cdc.gov/std/Chlamydia2010/ default.htm.
(15.) Jin F, Prestage GP, Mao L, et al. Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex Transm Infect. 2007;83:113-119.
(16.) Ng BF, Buffer LM, Horvath T, Rutherford GW. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev. 2011;3:CD001220.
(17.) Heiligenberg M, Rijnders B, Schim van der Loeff MF, et al. High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. Sex Transm Dis. 2012;39:8-15.
(18.) Landes M, Thorne C, Barlow P, et al. Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe. Eur J Epidemiol. 2007;22:925-936.
(19.) Holtgrave DR, Crosby RA. Social capital, poverty, and income inequality as predictors of gonorrhoea, syphilis, chlamydia and AIDS case rates in the United States. Sex Transm Infect. 2003;79:62-64. http://bmj-sti.highwire.org/content/79/1/62.full.
(20.) Wand H, Guy R, Donovan B, McNulty A. Developing and validating a risk scoring tool for chlamydia infection among sexual health clinic attendees in Australia: a simple algorithm to identify those at high risk of chlamydia infection. BMJ Open. 2011;1:e000005. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191384/?tool=pubmed.
(21.) Peterman TA, Tian LH, Metcalf CA, et al, RESPECT-2 Study Group. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med. 2006;145:564-572.
(22.) Sweet T, Welles SL. Associations of sexual identity or same-sex behaviors with history of childhood sexual abuse and HIV/STI risk in the United States. J Acquir Immune Defic Syndr. 2012;59:400-408. http://www.natap.org/2012/HIV/032312_02.htm.
(23.) Greenwald E, Beck-Sague CM, Hammerschlag MR, Black CM. Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics. 2009;124:79-86.
(24.) Bechtel K. Sexual abuse and sexually transmitted infections in children and adolescents. Curt Opin Pediatr. 2010;22:94-99.
(25.) Scott Lamontagne D, Baster K, Emmett L, et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16-24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex Transm Infect. 2007;83:292-303.
(26.) Hamlyn E, McAllister J, Winston A, et al. Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile? Sex Transm Infect. 2006;82:21-23. Erratum in Sex Transm Infect. 2006;82:422.
(27.) Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis. 2010;201(suppl 2):S114-S125. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150527/.
(28.) Rasmussen SJ, Eckmann L, Quayle AJ, et al. Secretion of proinflammatory cytokines by epithelial cells in response to chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest. 1997;99:77-87. http://www. ncbi.nlm.nih.gov/pmc/articles/PMC507770/pdf/990077.pdf.
(29.) Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. JAIDS. 2010;53:537-543.
(30.) Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and recta-analysis. Sex Transm Dis. 2008;35:946-959.
(31.) McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS. 2001;15:105-110.
(32.) Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol. 1997;146:350-357.
(33.) Kilmarx PH, Mock PA, Levine WC. Effect of chlamydia trachomatis coinfection on HIV shedding in genital tract secretions. Sex Transm Dis. 2001;28:347-348. http://journals.lww.com/stdjourna/Fulltext/2001/06000/ Effe_of_Chlamydia_trachomatis_Coinfection_on_HIV.8.aspx.
(34.) Farley TA, Cohen DA, Wu SY, Besch CL. The value of screening for sexually transmitted diseases in an HIV clinic. J Acquir Immune Defic Syndr. 2003;33:642-648.
(35.) Calvet HM. Sexually transmitted diseases other than human immunodeficiency virus infection in older adults. Clin Infect Dis. 200;36:609-614. http://cid.oxfordjournals.org/content/36/5/609.full.pdf.
(36.) Berry SA, Ghanem KG, Page KR, Thio CI., Moore RD, Gebo KA. Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines. Sex Transm Infect. 2010;86:481-484. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066003/?tool=pubmed.
(37.) Berry S, Korthuis T, Mathews C, et al. Gonorrhea and chlamydia testing increasing, but not on par with syphilis and lipid testing in a consortium of HIV clinics. 19th Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012. Seattle. Abstract 891. http://www.retroconference.org/2012b/PDFs/891.pdf.
(38.) Hamel MJ, Judson FN, Rietmeijer CA. Screening for chlamydia trachomatis in an anonymous and confidential HIV counseling and testing site: feasibility and prevalence rates Sex Transm Dis. 2001;28:153-157. http://journals.lww.com/stdjournal/Fulltext/2001/03000/ Screening_for_Chlamydia_trachomatis_in_an.6.aspx.
(39.) Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis. 200;41:67-74. http://cid.oxfordjournals.org/content/41/1/67.full.
(40.) Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol. 2010;48:1827-1832. http://jcm.asm.org/content/48/5/1827.long.
(41.) Owens SL, Arora N, Quinn N, Peeling RW, Holmes KK, Gaydos CA. Utilising the internet to test for sexually transmitted infections: results of a survey and accuracy testing. Sex Transm Infect. 2010;86:112-116.
(42.) Warner L, Newman DR, Austin HD, et al; Project RESPECT Study Group. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol. 2004;159:242-251. http://aje.oxfordjournals.org/content/159/3/242.full.
(43.) Warner L, Stone KM, Macaluso M, Buehler JW, Austin HD. Condom use and risk of gonorrhea and chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis. 2006;33:36-51. http://www.region8ipp.com/Docs/Articles/warner_condoms_methods_sti06.pdf.
(44.) Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis. 2003;30:49-56.
(45.) Warner L, Klausner JD, Rietmeijer CA, et al; Safe in the City Study Group. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med. 2008;5(6):e135. http://www.plosmedicine.org/ article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050135. To access this video, go to http://www.safeinthecity.org.
(46.) Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: the WILLOW Program. J Acquir Immune Defic Syndr. 2004;37(suppl 2):S58-$67. For details on the WILLOW Program, go to http://www.cdc.gov/hiv/toples/research/prs/resources/ factsheets/WILLOW.htm#ref1.
(47.) DiClemente RJ, Wingood GM, Rose ES, et al. Efficacy of sexually transmitted disease/human immunodeficiency virus sexual risk-reduction intervention for African American adolescent females seeking sexual health services: a randomized controlled trial. Arch Pediatr Adolesc Med. 2009;163:1112-1121. http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/ archpediatrics.2009.205.
(48.) Sznitman SR, Carey MP, Vanable PA, et al. The impact of community-based sexually transmitted infection screening results on sexual risk behaviors of African American adolescents. J Adolesc Health. 2010;47:12-19. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2917098/?tool=pubmed.
(49.) Karunakaran KP, Yu H, Foster LJ, Brunham RC. Development of a Chlamydia trachomatis T cell vaccine. Hum Vaccin. 2010;6:676-680. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056063/ ?tool=pubmed.
(50.) Centers for Disease Control and Prevention (CDC). Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep. 2008;57(RR-9):1-83. http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5709a1.htm.
(51.) Golden MR, Hogben M, Handsfield HH, St Lawrence JS, Potterat JJ, Holmes KK. Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis. 2003;30:490-496. http://journals.lww.com/stdjournal/Fulltext/2003/06000/ Partner_Notification_for_HIV_and_STD_in_the_United.4.aspx.
(52.) St Lawrence JS, Montano DE, Kasprzyk D, et al. STD screening, testing, case reporting, and clinical and partner notification practices: a national survey of US physicians. Am J Public Health. 2002;92:1784-1788. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1447329/?tool=pubmed.
(53.) Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352:676-685. http://www.nejm.org/doi/full/10.1056/NEJMoa041681.
(54.) Estcourt C, Sutcliffe L, Cassell J, et al. Can we improve partner notification rates through expedited partner therapy in the UK? Findings from an exploratory trial of accelerated partner therapy (APT). Sex Transm Infect. 2012;88:21-26. http://sti.bmj. com/content/88/1/21.long.
(55.) Kretzschmar M, Satterwhite C, Leichliter J, Bcrman S. Effects of scrcening and partner notification on chlamydia positivity in the United States: a modeling study. Sex Transm DIS. 2012;39:325-331.
(56.) Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:No. RR-12. http://www.cdc.gov/std/treatment/2010/.
(57.) Steedman NM, McMillan A. Treatment of asymptomatic rectal Chlamydia trachomatis: is single-dose azithromycin effective? Int J STD AIDS. 2009;20:16-18.
Table 1. Key questions about the course of chlamydia remain unanswered Key question What data say so far What is the duration of "Ethical considerations are a untreated, uncomplicated genital major challenge in studying the chlamydial infection in humans? natural history of untreated chlamydia.... Taking these ethical challenges into consideration, designing longitudinal studies on the natural history of chlamydia will be difficult." Which clinical factors influence "... we have limited knowledge resolution of untreated, about the clinical factors that uncomplicated genital chlamydial influence the duration of infection in humans? untreated, uncomplicated genital chlamydial infections in humans." Which host immune responses occur "... there are few studies of in uncomplicated genital host immune responses in humans chlamydial infections in humans, with uncomplicated genital and which genetic determinants of chlamydial infections." the host modulate these immune responses? Which biological properties of C "... we have very limited trachomatis influence resolution knowledge of the impact of of uncomplicated genital biological characteristics of C chalamydial infections in humans? trachomatis on outcomes of uncomplicated genital chlamydial infection in humans, including most importantly, the duration of infection." Source: Geisler et al. (6) Table 2. Chlamydia prevalence and incidence in 527 HIV positive US adults Baseline prevalence MSM MSW Women (n = 365) (n = 73) (n = 119) Anorectal 7% 0% 2% Oropharyngeal 1% 1% 2% Genitourinary 2% 0% 3% Incidence at 6-month visit MSM MSW Women (n = 365) (n = 73) (n = 119) Anorectal 5% 0% 0% Oropharyngeal 2% 0% 0% Genitourinary 1% 0% 0% MSM, men who have sex with men; MSW, men who have sex with women. Source: Mayer et al. (12) Table 3. Risk factors for chlamydia and other STIs in people with HIV HIV positive participants First author Location(s) Year(s) No. of participants Mayer (12) SUN Study 2004-2006 365 MSM, 73 MSW, participants 119 women in Denver, Minneapolis, St. Louis, Providence Heiligenberg (17) Netherlands, 2007-2008 659 MSM academic hospital outpatient clinics Landes (18) Western 1999-2005 1050 pregnant Europe and women Ukraine HIV positive participants First author Risk factors (95% GI) Mayer (12) For prevalent STIs* in MSM: > 4 partners: OR 4.81 (2.59-9.13) For incident STIs* in MSM: > 4 partners: OR 3.44 (1.82-7.56) Polysubstance abuse (not marijuana): OR 5.0 (1.82-13.2) Heiligenberg (17) For CT, NG, or SY Age < 40: OR 2.5 (1.3-5.0) Sex with > 2 sex partners: OR 2.1 (1.2-3.5) Sharing sex toys: OR 2.2 (1.0-4.9) For CT or NG: Age 40-44 vs older: OR 2.4 (1.1 5.3) Age < 40: OR 2.4 (1.1-5.4) Enema before sex: OR 2.4 (1.3-4.4) Drugs during sex: OR 2.4 (1.4-4.0) Landes (18) For CT, SY, or TV Being single: OR 3.9 (1.2-12.7) Sex partner of IDUs: OR 3.8 (1.4-10.4) CD4 count <200: OR 5.4 (1.0-28.1) Chlamydia trachomatis; MSM, men who have sex with men; MSW men who have sex with women; NG, Neisseria gonorrhoea; OR, odds ratio; SY, syphilis; TV, Trichomonas vaginalis. * STIs include syphilis and oropharyngeal, rectal, or genitourinary tract N gonorrhoea and/or C trachomatis. Table 4. Risk factors for chlamydia and other STIs in the general population General population First author Location(s) Year(s) No. of participants Holtgrave (19) 48 contiguous 1999 Not stated United States Wand (20) Sydney, 1998- 3805 MSM, 5M:) Australia, 2009 MSW, 7084 women sexual health clinics Peterman (21) STI clinics in 1999- 1236 women, Denver, Long 2000 1183 men attending Beach, Newark STI clinic First author Risk factors (95% CI) Holtgrave (19) For CT * Poverty: r 0.358, [r.sup.2] 0.128, P < 0.01 Social capital: [dagger] r -0.532, [r.sup.2] 0.283, 11 < 0.01 Income inequality: r 0.395, [r.sup.2] 0.156, P < 0.01 Wand (20) For CT in MSM: ([double dagger]) Age < 25 vs 40+: OR 1.47, P = 0.005 Age 25-29 vs 40+: OR 1.58, P < 0.001 Age 30-39 vs 40+: OR 1.42, P = 0.006 Current vs never smoker: OR 1.19, P = 0.05 Genital or anal vs no symptoms: OR 2.86, P < 0.001 Inconsistent condom use: OR 1.51,P<0.001 CT for women: ([double dagger]) Never married: OR 1.2:5, P = 0.05 Minority: OR 1.33, P < 0.001 Inconsistent condom use: OR 1.51, P<0.001 Peterman (21) For recurrent CT 15-25 vs older: OR 2.2 (1.7-2.9) Black vs white: OR 2.0 (1.3-3.1) Hispanic vs white: OR 1.9 (1.2-2.9) Infection at initial visit: OR 1.6 (1.2-2.2) 2-4 partners vs 1: OR 1.7 (1.3-2.3) CT, Chlamydia trachomatis; MSM, men who have sex with men; MSW, men who have sex with women; NG, Neisseria gonorrhoea; OR, odds ratio; SY, syphilis; TV, Trichomonas vaginalis. * Stated as Pearsou product moment correlation coefficients. ([dagger]) The central features of social capital are "trust, reciprocity, and cooperation among members of a social network that aims to achieve common goals." (19) ([double dagger]) Other variables-including 1, 2, or 3 or more sex partners in the last months versus none, STI symptoms, and contact with an STI case--were also associated with higher odds for chlamydia in MSM and women. Risk factors for heterosexual men were being single, minority status, being unsure about HIV status, inconsistent condom use, increased number of female sex partners in tale past 3 months, anal/genital symptoms, and presenting for STI screening or being a contact of an STI case. Table 5. HRSA guidelines for chlamydia and gonorrhea screening in people with HIV Women If negative If positive * Screen sexually * Counsel about * Treat patient active women at safer sex and * Refer partners) risk avoiding STIs of previous 60 * Screen all at * Repeat every 6 days for baseline to 12 months; more evaluation and * Frequency of frequently if at treatment subsequent testing higher risk * Counsel about depends on risk safer sex factors * Screen all sites of possible exposure: pharynx (for gonorrhea screening), cervix/vagina; urethra; rectum Men If negative If positive * Screen sexually * Retest every 3 * Treat active men at to 6 months for * Refer partner(s) risk, especially patients with risk of previous 60 MSM Screen all at factors days for baseline evaluation and * Frequency of treatment subsequent testing * Counsel about depends on risk safer sex factors * Screen sites of possible exposure: pharynx (for gonorrhea screening), rectum; urethra (consider for MSM with history of unprotected insertive intercourse in preceding year) Figure 1 Chlamydia case rates in US women rose every year from 2000 through 2010, the last year for which the CDC has data. (14) Chlamydia case rates in US women Per 100,000 2000 396.3 2001 429.6 2002 445.0 2003 463.6 2004 480.6 2005 492.2 2006 510.8 2007 539.8 2008 579.4 2009 586.7 2010 610.6 Note: Table made from bar graph.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|